DARA BioSciences, Inc. KRN5500 Reduces Allodynia in Patients With Neuropathic Pain

RALEIGH, N.C., Dec. 14, 2010 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA) announced today additional positive results from its successfully completed KRN5500 Phase 2a Clinical Study for treatment of neuropathic pain in patients with cancer. Statistically significant primary endpoint results were released earlier.

MORE ON THIS TOPIC